CG Oncology

The USA-based company's lead candidate, cretostimogene grenadenorepvec (CG0070), is a targeted oncolytic intravesically-delivered immunotherapy. In BCG unresponsive non-muscle invasive bladder cancer (NMIBC) and other cancer types, the agent has shown promise in potentially delivering a safe and effective therapy alone as well as in combination with other therapies.